A Multicenter, Open-label, Uncontrolled, Long-term Trial to Demonstrate the Safety and Efficacy of 1% OPA-15406 Ointment in Adult Patients with Atopic Dermatitis and of 0.3% and 1% OPA-15406 Ointments in Pediatric Patients with Atopic Dermatitis

Administration of 1% OPA-15406 ointment to adult patients with AD and 0.3% or 1% OPA-15406 ointment to pediatric patients with AD for 52 weeks raised no marked safety issues and was well tolerated by most of these patients. In addition, the efficacy of OPA-15406 ointment was demonstrated, such as its improving effect on the severity of rash based on IGA and EASI scores after administration for 52 weeks.